Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biological agent: A nine-year multicenter cohort study

Prior research had confirmed that biologic therapies can reactivate hepatitis B virus (HBVr) and hepatitis C in patients with psoriasis. Psoriasis patients with HBsAg-seropositive, HBeAg-seropositive, TNF- α inhibitor therapy, have a higher risk of HBVr and should be more closely monitored.

Source: Journal of the American Academy of Dermatology - December 6, 2019 Category: Dermatology Authors: Hsien-Yi Chiu, Ying-Ming Chiu, Nien-Feng Chang Liao, Ching-Chi Chi, Tsen-Fang Tsai, Chang-Yu Hsieh, Tsu-Yi Hsieh, Kuo-Lung Lai, Tsu-Man Chiu, Nan-Lin Wu, Rosaline Chung-yee Hui, Chaw-Ning Lee, Ting-Shun Wang, Po-Hua Chen, Chao-Chun Yang, Yu-Huei Huang Source Type: research